Accessibility Menu

Hologic (Nasdaq: HOLX) reported earnings on July 30. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended June 23 (Q3), Hologic met expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue grew and GAAP earnings per share dropped significantly.

Gross margins contracted, operating margins expanded, net margins dropped.

Revenue details
Hologic reported revenue of $470.2 million. The 17 analysts polled by S&P Capital IQ predicted sales of $475.0 million on the same basis. GAAP reported sales were 4.2% higher than the prior-year quarter's $451.1 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.35. The 21 earnings estimates compiled by S&P Capital IQ predicted $0.34 per share. GAAP EPS of $0.09 for Q3 were 36% lower than the prior-year quarter's $0.14 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 61.7%, 20 basis points worse than the prior-year quarter. Operating margin was 17.6%, 30 basis points better than the prior-year quarter. Net margin was 5.0%, 300 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $505.8 million. On the bottom line, the average EPS estimate is $0.36.

Next year's average estimate for revenue is $1.93 billion. The average EPS estimate is $1.37.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 684 members out of 706 rating the stock outperform, and 22 members rating it underperform. Among 174 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 168 give Hologic a green thumbs-up, and six give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hologic is outperform, with an average price target of $23.11.

Read Next

About the Author

Seth Jayson
Seth Jayson is an advisor on The Motley Fool’s Trends service, overseeing the AI and Spotters segments of the scorecard. Seth closely follows technology companies, particularly hyperscalers and their suppliers. He also stays up to date and recommends companies in homebuilding, specialty online, defense, aerospace, and other sectors. He has spent more than two decades researching, reporting on, and recommending stocks to Motley Fool members. A former Motley Fool member himself, Seth holds a B.A. from Carleton College and two master’s degrees from NYU and the University of Missouri in art history and journalism respectively.
TMFRizzChicken

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Stocks Mentioned

Hologic Stock Quote
Hologic
NASDAQ: HOLX
--
--
Stock Advisor

Motley Fool Stock Advisor’s Latest Pick

Get Access
---% Avg Return

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services